.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,349,353

« Back to Dashboard

Details for Patent: 8,349,353

Title:Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s): Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Harris; Jeffrey P. (La Jolla, CA), Lebel; Carl (Malibu, CA), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Dellamary; Luis A. (San Marcos, CA)
Assignee: Otonomy, Inc. (San Diego, CA) The Regents of the University of California (Oakland, CA)
Filing Date:Jun 29, 2009
Application Number:12/493,611
Claims:1. A method of treating an otic disease or condition selected from ear cancer and autoimmune ear disease (AIED) comprising administering to an individual in need thereof an intratympanic composition comprising: between about 0.01% to about 50% by weight of a multiparticulate cytotoxic agent, or pharmaceutically acceptable salt thereof; and a polyoxyethylene-polyoxypropylene copolymer in an amount sufficient to provide a gelation temperature of between about room temperature and about body temperature; wherein the intratympanic composition provides release of the cytotoxic agent into the ear for a period of at least 5 days after a single intratympanic administration provided that the cytotoxic agent is a non-corticosteroid cytotoxic agent.

2. The method of claim 1, wherein the multiparticulate cytotoxic agent is essentially in the form of micronized particles.

3. The method of claim 1, wherein the cytotoxic agent is selected from an antimetabolite, an antifolate, an alkylating agent and a DNA intercalator.

4. The method of claim 1, wherein the cytotoxic agent is selected from methotrexate, thalidomide, cyclophosphamide, lenalidomide and CC-4047.

5. The method of claim 1, wherein the polyoxyethylene polyoxypropylene copolymer is poloxamer 407.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc